_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The platform’s technology works as a compression algorithm for molecular testing
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Sputnik M is a new member of the Sputnik vaccines family
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Subscribe To Our Newsletter & Stay Updated
